Strategies to Identify and Delay Brain Metastases in HER2+ Breast Cancer

Video

A brief review on how best to identify, delay, or avoid brain metastases in patients diagnosed with metastatic HER2+ breast cancer.

Recent Videos
4 experts in this video
4 experts in this video
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
4 experts in this video
4 experts in this video
5 experts in this video
4 experts in this video
4 experts in this video
Related Content
96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

Elyse Swallow;Jessica Maitland;Kirthana Sarathy;Ellen Sears;Yasir Nagarwala;Janelle DePalantino;Eric Kruep;Corey Pelletier;Sebastian Kloss;Tomer Wasserman
April 18th 2025
Article
Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.

Bria-IMT Enhances Survival vs Sacituzumab Govitecan in HR+ Breast Cancer

Roman Fabbricatore
April 17th 2025
Article

No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Reducing Post-Mastectomy Disparities in Breast Cancer Minority Populations

Rachel A. Greenup, MD, MPH
December 23rd 2024
Podcast

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

100 Non-Pharmacological Interventions for Managing Abemaciclib-Associated Adverse Events in Patients With Early/Advanced HR+/HER2– Breast Cancer: A US-Based Health Care Provider Survey

100 Non-Pharmacological Interventions for Managing Abemaciclib-Associated Adverse Events in Patients With Early/Advanced HR+/HER2– Breast Cancer: A US-Based Health Care Provider Survey

Alexandra Vitko;Pamela K Ginex;Kelli Thoele;Qinli Lily Ma;Astra Liepa;Wambui Gathirua-Mwangi;Elyse Hall Panjic, PharmD, BCOP;Engels Chou;Jodi L Taraba;Hilary Ellis;Charlotte Clewes;Joanna de Courcy;Hope S. Rugo, MD
April 15th 2025
Article
102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

Charlotta Wadsten;Karuna Mittal;Pat W. Whitworth;Chirag Shah, MD;Frank Vicini, MD;Naamit Gerber;Melissa Krystel-Whittemore;Clayton C. Yates;Balasubramanyam Karanam;Walter Bell;Charles E. Cox, MS, FACS;Abigail Beard;Geza Acs;Steven C. Shivers;David J. Dabbs;Jess Savala;Mark Mentrikoski;Troy Bremer
April 14th 2025
Article